Trump Says the "Fat Shot" Will Soon Cost $150, Meet the Reporter Who Made Him Say
- Dave Knapp
- 9 hours ago
- 1 min read
More importantly, what does all this mean?
Original posted at obesity.news/ on Oct 17, 2025
Every once in a while, a single question changes everything.
On October 16, 2025, Max Beyer, pharma reporter at Endpoints News, asked President Trump a question about GLP-1 pricing and the administration’s plans under the Most Favored Nation (MFN) drug policy. What came next made global headlines: Trump said the “fat shot” would cost $150 in the US.
That one sentence sent Eli Lilly and Novo Nordisk stock sliding, shook the investor world, and lit up every GLP-1 community online. But here’s the thing, Max didn’t ask it as a gotcha question. He asked it because millions of patients living with obesity are desperate for an answer about access and affordability.
I sat down with Max to talk about what it felt like in that moment, what he’s hearing from Washington insiders now, and what this all means for the future of GLP-1 pricing.
Because this isn’t just about politics. It’s about whether the people who need these medications most will ever be able to afford them.
👇 Watch our full conversation below.
This article is reader-supported on Substack.
To receive new posts and support my work,
consider becoming a free or paid subscriber.